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Voltage-gated sodium channels (VGSC) are multi-molecular protein complexes expressed
in both excitable and non-excitable cells. They are primarily formed by a pore-forming
multi-spanning integral membrane glycoprotein (α-subunit) that can be associated with
one or more regulatory β-subunits. The latter are single-span integral membrane proteins
that modulate the sodium current (INa) and can also function as cell adhesion molecules.
In vitro some of the cell-adhesive functions of the β-subunits may play important phys-
iological roles independently of the α-subunits. Other endogenous regulatory proteins
named “channel partners” or “channel interacting proteins” (ChiPs) like caveolin-3 and
calmodulin/calmodulin kinase II (CaMKII) can also interact and modulate the expression
and/or function of VGSC. In addition to their physiological roles in cell excitability and cell
adhesion,VGSC are the site of action of toxins (like tetrodotoxin and saxitoxin), and pharma-
cologic agents (like antiarrhythmic drugs, local anesthetics, antiepileptic drugs, and newly
developed analgesics). Mutations in genes that encode α- and/or β-subunits as well as the
ChiPs can affect the structure and biophysical properties of VGSC, leading to the develop-
ment of diseases termed sodium “channelopathies”. This review will outline the structure,
function, and biophysical properties of VGSC as well as their pharmacology and associated
channelopathies and highlight some of the recent advances in this field.
Keywords: voltage-gated sodium channels, channelopathies, electrophysiology, sodium channels, pharmacology,
biophysics
INTRODUCTION
In mammals, 11 genes (SCN1A–SCN11A) encode a family of nine
functionally expressed voltage-gated sodium channels (VGSC;
Nav1.1–Nav1.9) that share more than 50% amino acid sequence
homology (Catterall et al., 2005). α-subunits encoded by these
genes are organized into four homologous domains (DI–DIV),
each one of which is composed of six transmembrane segments.
Segments 1 through 4 of each domain form the voltage sensor,
while segments 5 and 6 (and their connecting linker the P-loop)
compose the pore region. In addition to the α-subunit, VGSC
also include β-subunits (which are mainly regulatory molecules)
as integral parts of the channel. VGSC can interact with other
endogenous proteins called “channel partners” or “channel inter-
active proteins” (ChiPs) that modulate channel expression and/or
function. The last group currently includes caveolin-3 (Lu et al.,
1999; Yarbrough et al., 2002; Vatta et al., 2006; Cronk et al., 2007),
calmodulin/calmodulin kinase II (CaMKII; Maier and Bers, 2002;
Tan et al., 2002; Wagner et al., 2006; Pitt, 2007), connexin-43 (Sato
et al., 2011; Chkourko et al., 2012), telethonin (Mazzone et al.,
2008), plakophilin (Sato et al., 2009), ankyrins (Kordeli et al., 1995,
1998; Davis et al., 1996; Garrido et al., 2003; Mohler, 2006), neu-
ronal precursor cell-expressed developmentally down regulated
4 (nedd4; Ingham et al., 2004; Rougier et al., 2005), fibroblast
growth factor homologous factors (FHFs; Liu et al., 2001, 2003b;
Laezza et al., 2007; Dover et al., 2010; Wang et al., 2011; Goldfarb,
2012), membrane-associated guanylate kinase synapse-associated
proteins (SAPs; Petitprez et al., 2011; Milstein et al., 2012), and
the syntrophin/dystrophin complex (Haenggi and Fritschy, 2006;
Shao et al., 2009).
Mutations in the genes encoding the VGSC have been associ-
ated with a wide variety of diseases including Dravet syndrome
and other types of epilepsy (Claes et al., 2001; Mantegazza et al.,
2005; Mullen and Scheffer, 2009), pain-related syndromes [which
includes congenital insensitivity to pain (CIP), primary ery-
thromelalgia (PE), and paroxysmal extreme pain disorder (PEPD)
(Dib-hajj et al., 2009; Lampert et al., 2010)], and cardiac arrhyth-
mias [which includes congenital long QT syndrome (LQTS) type
3 (Wang et al., 1995), Brugada Syndrome (BS; Probst et al., 2003),
progressive cardiac conduction defect (Scott et al., 1999), sick sinus
syndrome (Benson et al., 2003), atrial fibrillation (AF; Olson et al.,
2005; Darbar et al., 2008), slow ventricular conduction (Chambers
et al., 2010; Sotoodehnia et al., 2010), and atrial stand still (Tan,
2006; Remme et al., 2008)]. Epigenetic up regulation of VGSC
has recently been associated with aggressive metastatic carcinoma
of prostate (Nav1.7) and breast (Nav1.5) (Onkal and Djamgoz,
2009). The up regulation of the VGSC seems to occur early in
the dissemination of this type of cancer and ignite the metasta-
tic status (the VGSC expression positively correlated in vivo with
invasiveness and therefore metastatic spread) (Onkal and Djam-
goz, 2009). Because of their central role in the pathophysiology
of these diseases, VGSC are clear pharmacological targets as sites
of action for antiepileptic drugs, newly developed analgesics and
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antiarrhythmic drugs, and potential disease markers in metastatic
carcinomas (prostate, breast).
This review will focus on the structure, function, and biophysics
of the VGSC, as well as their pharmacology, the sodium chan-
nel “partners” (or “ChiPs”) currently identified and the sodium
“channelopathies”.
STRUCTURE OF VGSC
Voltage-gated sodium channels are heteromeric integral mem-
brane glycoproteins that can be differentiated by their primary
structure, kinetics, and relative sensitivity to the neurotoxin
tetrodotoxin (TTX). They are composed of an α-subunit of
approximately 260 kDa (∼2000 amino acids), that is associated
with one or more regulatory β-subunits (β1–β4) of approximately
35 kDa each (Catterall, 2000). We will describe in detail both
subunits (α and β) that conform the VGSC.
α-SUBUNITS
Ten different mammalian α-subunit isoforms (NaV1.1–NaV1.9
and NaX) have been characterized (Table 1) and at least seven
of them are expressed in the nervous system. NaV1.1, NaV1.2,
NaV1.3, and NaV1.6 isoforms are mainly expressed in the central
nervous system (CNS). In contrast, NaV1.7, NaV1.8, and NaV1.9
isoforms are predominantly located in the peripheral nervous sys-
tem (PNS; Ogata and Ohishi, 2002), are known to accumulate
in the region of peripheral nerve injury and may be important in
chronic, neuropathic pain (Devor, 2006; Table 1). In recent reports
SCN10A/NaV1.8 has also been identified in human hearts (Facer
et al., 2011; Yang et al., 2012) and in intracardiac neurons (Verkerk
et al., 2012), where genetic variations in the SCN10A gene have
been associated with alterations in the PR interval, QRS duration,
and ventricular conduction (Chambers et al., 2010; Sotoodehnia
et al., 2010). Because these isoforms (NaV1.1–1.3, NaV1.6–1.9)
are mainly localized in nervous tissue they are generally referred
as “brain type” or “neuronal-type” sodium channels. NaV1.4 iso-
form is mainly expressed in skeletal muscle, while NaV1.5 is the
cardiac-specific isoform. The isoform referred to as “NaX channel”
[also named NaG/SCL11 (rats), Nav2.3 (mice), and/or hNav2.1
(humans)] identifies a subfamily of sodium channel-like proteins
(George et al., 1992). This channel has significant differences in
the amino acid sequence in the voltage sensor, inactivation gate,
and pore region when compared to the rest of VGSC (George et al.,
1992; Goldin et al., 2000). NaX is normally expressed in a variety
of organs including the heart, skeletal muscle, uterus, dorsal root
ganglia (DRG), and brain [mainly in the circumventricular organs
(CVOs)]. The difficulties in the characterization of the biophys-
ical properties of this channel are mainly due to lack of success
in expressing the functional protein in heterologous expression
systems. Hiyama et al. (2002) generated a mouse model in which
the NaX gene was knocked out. This group confirmed that Nax
channel was expressed in neurons in the CVOs that play a funda-
mental role controlling body fluid and ionic balance. This group
reported that under thirst conditions, mice lacking Nax showed
hyperactivity of the neurons in these areas and ingested excessive
salt, while wild-type mice did not. This led the investigators to pro-
pose that NaX was involved in the mechanism that senses sodium
levels in the brain, where this protein might sense extracellular
sodium concentration (Hiyama et al., 2002; Noda, 2006).
Each α-subunit is arranged in four homologous domains (DI–
DIV) that contain six transmembrane segments (S1–S6; Figure 1).
Using cryo-electron microscopy Sato et al. (2001) showed that
these four domains are arranged around the central pore of the
channel. Segment 4 of each domain contains a high concentration
of positive charges (mostly arginine) and functions as the core of
the voltage sensor responsible for the voltage-dependent activa-
tion of the channels. Segment 6 from all four domains forms the
inner surface of the pore. The hairpin-like loop between segments
5 and 6 [S5–S6 hairpin-like P(ore)-loop] is part of the pore of the
channel and forms a narrow (ion-selective) filter that controls the
ion selectivity and permeation at the extracellular side of the pore
(Catterall, 2000; Yu and Catterall, 2003; George, 2005).
Payandeh et al. (2011) recently reported the crystal structure
of NaVAb, a VGSC found in the bacterium Arcobacter butzleri.
NaVAb is part of the NachBac channel family, which is a well-
established model to study vertebrate NaV and CaV channels (Ren
et al., 2001; Koishi et al., 2004; Payandeh et al., 2011). Payandeh
et al. (2011) were able to capture this channel in the close configu-
ration when the pore was closed with four activated voltage sensors
at a resolution limit of 2.7 Å. Payandeh’s work provides the first
insight into the structural basis for voltage-dependent gating ion
selectivity and drug block in VGSC. The pore consists of an outer
tubular vestibule, a selectivity filter, a central cavity (which can
lodge partially hydrated sodium ions) and an intracellular acti-
vation gate. The helices that constitute the pore are positioned
to stabilize cations in the central cavity through helical-dipole
interactions (Doyle et al., 1998; Jogini and Roux, 2005). A sec-
ond P2-helix forms an extracellular funnel and represents a highly
conserved element in sodium channels (Payandeh et al., 2011).
Payandeh and coworkers proposed that in NaVAb the ion con-
duction pathway is electronegative and the selectivity filter (mainly
composed of negatively charged glutamate (Glu) side chains)
forms the narrowest constriction near the extracellular side of
the membrane. There are 4 Glu 177 side chains that form a 6.5-
Å× 6.5-Å scaffold with an orifice of approximately 4.6 Å wide. A
profuse mesh of amino acid residue interactions, including hydro-
gen bonds between glutamine from the P-helix and the carbonyl
of Glu, stabilizes the selectivity filter. The radius of the pore sug-
gests that hydrated Na+ ions can conduct through the channel.
Free diffusion then allows the hydrated Na+ to enter the central
cavity and move through the open activation gate toward the cyto-
plasm (Payandeh et al., 2011). This permeation pathway contrasts
with the selectivity filter in K+ channels, which is much nar-
rower. In this case the smaller radius of the pore can only conduct
dehydrated K+ ions through direct interactions with backbone
carbonyls through a long, narrow pore (Morais-Cabral et al., 2001;
Ye et al., 2010).
Identification of the primary structure of VGSC led to the
development of the “sliding helix” (Catterall, 1986b) and the “heli-
cal screw” (Guy and Seetharamulu, 1986) models (validated by
structure-function studies) to better understand how the volt-
age sensor operates. Both models suggest that positively charged
residues in segment 4 within each domain serve as the gating
charges moving outward across the membrane as a consequence
of membrane depolarization, initiating the activation process
(Catterall, 1986a,b; Guy and Seetharamulu, 1986; Catterall et al.,
2010). Catterall and coworkers have extensively described these
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two models. Basically, four to seven residues positively charged
within segment 4 would pair negatively charged residues in seg-
ments 1, 2, and/or 3. In this configuration, positively charged
residues in segment 4 are pulled inward by the electric field of the
resting membrane potential which is negative. As depolarization
progresses, the change in the polarity of the membrane potential
relieve the electrostatic force and the segments 4 move outward
allowing each positive charged amino acid in the segment 4 pairs
a negatively charged one. As described by Catterall (2010), this
outward movement of the gating charges in segments 4 pulls the
linker between segments 4 and 5, curves the segment 6 and initi-
ates the opening of the central pore of the channel. The movement
of charged particles to activate the sodium conductance (“gating
charges” or “gating current ”) was first predicted by Hodgkin and
Huxley (Hodgkin and Huxley, 1952; Catterall, 2010), but Arm-
strong and Bezanilla (1973) were the first ones that measured it
in 1973, combining the techniques of internal perfusion, voltage-
clamp, and signal average. Using similar techniques, Keynes and
Rojas (1973) confirmed the existence of the gating current the
same year. Armstrong and Bezanilla (1974) reported additional
properties of this current and strong evidence linking it to the
gating of the sodium channels the following year.
β-SUBUNITS
These are integral proteins as well, composed of one extracel-
lular domain (ECD, N-terminal domain), one transmembrane
domain, and one intracellular domain (C-terminal domain). The
β-subunits are expressed in excitable and non-excitable cells within
the nervous system and the heart, and there is some evidence sug-
gesting that these proteins can be expressed in the cells even in the
absence of the α-subunit (Patino and Isom, 2010; Table 2). One
or more regulatory β-subunits (β1–β4) can associate with one
α-subunit. An individual α-subunit can be associated with one
non-covalently (β1 or β3) and one covalently (β2 or β4) linked
β-subunits (Yu and Catterall, 2003; Catterall et al., 2005; Patino
and Isom, 2010). The role of β-subunits has been reviewed in
detail by Patino and Isom (2010). The authors remark that β-
subunits are regulatory proteins that can act both as cell adhesion
molecules (CAMs) and modulate the cell surface expression of
the VGSC, enhancing sodium channel density and cell excitabil-
ity. The latter may be a very important mechanism that regulates
nociceptor excitability in vivo (Lopez-Santiago et al., 2011). β1
association with contactin or neurofascin (NF)-186 also results in
increased VGSC cell surface expression (Kazarinova-Noyes et al.,
2001; McEwen and Isom, 2004). Furthermore, β1 and β2 are
ankyrin-binding proteins. Mice lacking ankyrin exhibit reduced
sodium current (I Na) density and abnormal I Na kinetics (Chauhan
et al., 2000), suggesting that β-subunits play important roles in the
VGSC–ankyrin complex (Patino and Isom, 2010). The interaction
betweenα- and β-subunits may be particularly critical at the nodes
of Ranvier of myelinated axons, since mice lackingβ1-subunit have
reduced numbers of nodes, alterations in the myelination process,
and drastically altered contacts between neurons and glial cells
(Chen et al., 2004). Even though proteins within nodal regions
are localized normally in these mice, association between VGSC
and contactin is disrupted. Loss of β1-subunit dependent protein–
protein interactions can lead to changes in the structure of the
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FIGURE 1 | Schematic representation of the α- and β-subunits of the
VGSC. The four homologous domains (I–IV) of the α-subunit are represented;
S5 and S6 are the pore-lining segments and S4 is the core of the voltage
sensor. In the cytoplasmic linker between domains III and IV the IFMT
(isoleucine, phenylalanine, methionine, and threonine) region is indicated. This
is a critical part of the “inactivation particle” (inactivation gate), and
substitution of aminoacids in this region can disrupt the inactivation process
of the channel. The “docking site” consists of multiple regions that include
the cytoplasmic linker between S4–S5 in domains III and IV, and the
cytoplasmic end of the S6 segment in domain IV (*). Depending on the
subtype of β-subunit considered they could interact (covalently or
non-covalently) with the α-subunit.
Ranvier nodes and disrupted saltatory conduction (Chen et al.,
2004; Davis et al., 2004). Similar to the β1- subunit, β2 can also
modulate the expression of the channel at the cell surface and
affect I Na density (Isom et al., 1995). β2 (and β4) intracellular
domains can translocate into the nucleus and enhance SCN1A
expression, thus functioning as transcriptional regulators of the
VGSC α-subunit.
β-subunits are also critical for cellular migration. β1 and β2
mediate migration of fibroblasts (Xiao et al., 1999) and cancer
cells (Brackenbury and Isom, 2008), adhesion, and neurite out-
growth (β1 promotes and β2 inhibits this process, while β3 and
4 have no effect; Davis et al., 2004; McEwen et al., 2009). The
effects of β-subunits on cell migration, adhesion, and neurite out-
growth also depends on intracellular transduction events like the
activation of proto-oncogene tyrosine-protein kinase fyn by β1 to
promote neurite (axon and/or dendrite) outgrowth (Brackenbury
et al., 2008).
BIOPHYSICAL PROPERTIES OF VGSC
When the cell is depolarized, the outward movement of all seg-
ments 4 generates a conformational change that opens the pore
and thus activates the channel. This allows sodium to flow into
the cell down its electrochemical gradient. I Na reaches a maxi-
mum within milliseconds and then becomes smaller as the sodium
channel stops conducting ions and starts closing. The closure of
the channel during maintained depolarization is called inactiva-
tion. The activation and inactivation processes and the coupling
between them (in particular, the outward movement of the voltage
sensor) are voltage-dependent. All the downstream rearrangements
are voltage-independent. The refractoriness of the cell is related to
the inactivated sodium channels, which cannot reopen until they
are completely recovered. This mechanism protects the cell and
prevents firing during prolonged depolarization (Goldin, 2003).
The time that the channel remains in a specific state (open or
close) as well as the rate at which it transitions from one state to the
other affects its ionic conductance and thus the shape of the action
potential (AP). During the last decade most of the advances in the
biophysics of the ion channels has been obtained by expressing
the channels in isolated systems (cell lines or lipid bilayers). But
the interpretation of this data has been somehow challenging due
to the lack of the correct physiological context. The importance
of computational biology was first emphasized by Rudy and Silva
(2006) by trying to understand the context in which ion channels
operate. Still, such theoretical approach in electrophysiology was
initiated by Hodgkin and Huxley (1952). Hodgkin and Huxley
(1952) were the first that formulated a model of the AP based on
the findings of their pioneering work with voltage-clamp tech-
niques showing voltage-dependent changes in ionic conductance
in squid axons. The data reported by Hodgkin and Huxley (1952)
suggested that the inward flow of Na+ was responsible for the rapid
initial positive upstroke of the membrane potential, whereas the
outward flow of potassium determined the repolarization of the
membrane back to resting levels. The mathematical model was
designed to determine whether the sodium and potassium cur-
rents they identified could in fact generate an AP that was similar in
morphology to their AP experimental recordings. The model pro-
posed by Hodgkin and Huxley was reviewed in detail by Rudy and
Silva (2006). Rudy and Silva explained that in this model the con-
ductance of sodium and potassium currents was dependent upon
the open probability of a series of activation gates. The activation
gates in this model correspond to the α-subunits of the VGSC.
Each gate can transition from a closed state (open probability= 0)
to an open state (open probability= 1) that is independent of the
state of the other gates. An ion can only pass through when all
the gates (that is, the four α-subunits that constitute the tetramer
VGSC) are open (open probability= 1). Rudy and Silva (2006)
also pointed out that the original model has several limitations:
the model assumes that intracellular concentrations of Na+ and
K+ do not change during the AP, and it does not consider the
inactivation of the channel. It also assumes that opening and
closing transition rates are independent (Rudy and Silva, 2006).
Rudy and Silva proposed that since the VGSC inactivation has a
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Table 2 | Summary of the different types of β subunits associated with the different VGSC, and the related channelopathies associated with the
mutations in the genes that encode them (modified from Patino and Isom, 2010).
Gene Chromosome β subunit α subunit Expression Channelopathies Model Reference
SCN1B 19q13.1 β1 NaV1.1–NaV1.7 Central and peripheral
neurons, glia, skeletal,
and cardiac muscles.
Seizures and epileptic
syndromes:
febrile seizures,
Dravet syndrome,
temporal lobe epilepsy
H
H,M
H
Coward et al. (2001), Audenaert
et al. (2003), Chen et al. (2004),
Pertin et al. (2005, 2007), Scheffer
et al. (2007), O’Malley et al. (2009),
Orrico et al. (2009), Patino et al.
(2009)
Traumatic nerve injury H
SCN2B 11q23 β2 NaV1.1, NaV1.2,
NaV1.5–NaV1.7
Central and Peripheral
neurons, glia, cardiac
muscle.
Multiple sclerosis, M Coward et al. (2001), Pertin et al.
(2005), Lopez-Santiago et al.
(2006), O’Malley et al. (2009)
Neuropathic pain
(post-trauma)
M
Inflammatory pain,
traumatic nerve injury
M
H
SCN3B 11q23.3 β3 NaV1.1–NaV1.3,
NaV1.5
Central and periph-
eral neurons, adrenal
gland, kidney
Temporal epilepsy, H Casula et al. (2004), van Gassen
et al. (2009)
Traumatic nerve injury H
SCN4B 11q23.3 β4 NaV1.1, Na 1.2,
NaV1.5
Central and peripheral
neurons, glia, skeletal
and cardiac muscles.
Huntington’s disease H,M Oyama et al. (2006)
H, human; M, mouse.
greater probability of occurring when the channel is open, then
inactivation is highly dependent on activation. Thus the inde-
pendent gating of the Hodgkin and Huxley model would not be
valid. To improve the accuracy of the mathematical model, Rudy
and Silva (2006) suggest considering the dependence of a given
transition on the occupancy of different states of the channel. In
the case of the VGSC, the model should consider the dependence
of the inactivation transition on the probability that the chan-
nel occupies the open state. Finally, the authors report that the
different states and the dependence of transitions (both voltage-
dependent and independent) between states can then be more
accurately predicted using Markov-type models (the importance
of computational biology to study the integrated electrophysiol-
ogy of ion channels has been extensively reviewed by Rudy and
Silva (2006)).
Inactivation is the process by which an open-channel enters
a stable non-conducting conformation when the cell membrane
depolarizes. The inactivation process includes fast, slow and ultra-
slow inactivation. In addition, long-term inactivation FHF- and
β4-mediated are processes distinct from slow inactivation (Gold-
farb, 2012). In general, while isoforms Nav1.1–Nav1.4, Nav1.6,
and Nav1.7 have faster inactivation kinetics, Nav1.5, Nav1.8, and
Nav1.9 have slower inactivation.
Fast inactivation mimics a “ball-and-chain” mechanism, where
a cytoplasmic segment of the α-subunit of the VGSC (or inac-
tivating particle) occludes the pore by binding to a docking site
(Goldin, 2003). Rohl et al. (1999) were the group that first studied
the inactivating particle. It consists of a portion of the cytoplas-
mic linker connecting domains III and IV, with the critical region
centering on a 4-amino acid extent consisting of isoleucine (I),
phenylalanine (F), methionine (M), and threonine (T) (IFMT;
Goldin, 2003). Phenylalanine and threonine directly interact with
the docking site and the distance between I- and T-residues cor-
relates with the ability to inactivate the channel (Goldin, 2003).
Amino acid substitution within this critical region can disrupt
the inactivation of the channel (Kudora et al., 2000; Miyamoto
et al., 2001a,b). The docking site includes the cytoplasmic linker
connecting segments 4 and 5 in domains III and IV and the cyto-
plasmic end of segment 6 in domain IV. This “ball-and-chain”
mechanism is equivalent to the N-type inactivation described
for voltage-gated potassium channels (N-type fast inactivation),
which involves occlusion of the intracellular mouth of the pore
through binding of a short peptide segment from the N-terminal
(Rasmusson et al., 1998). Fast inactivation is important during AP
repolarization, and in some structures like mammalian nodes of
Ranvier (which practically lack phasic potassium channels) it is
the only repolarizing force besides the leakage current (Ulbricht,
2005).
Fast inactivation can be altered by the carboxyl (C)-terminus
of the channel. This is due to electrostatic interactions involving
the sixth helix in the C-terminus, which can modulate the inter-
action of the fast inactivating particle with its docking site. The
different amino acid composition of the C-terminus explains the
differences observed in fast inactivation between the VGSC iso-
forms (Mantegazza et al., 2001). Motoike et al. (2004) reported
that the C-terminus is actually part of the inactivation gate, as it
stabilizes the closed state minimizing the reopening of the chan-
nel. Mutations in the C-terminus disrupt fast inactivation and can
lead to the LQTS type 3 (Goldin, 2003).
Fast inactivation can also be modulated by the interaction
with β-subunits. The effect and mechanism is dependent on the
specific α- and β-subunits involved and the heterologous expres-
sion system being used to express the channel. For example, the
β1-subunit accelerates the recovery from inactivation of Nav1.5
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(Zimmer and Benndorf, 2002) and Nav1.2 (Chen and Cannon,
1995; McCormick et al., 1998, 1999) and shifts the voltage-
dependence of inactivation in the negative direction (Meadows
et al., 2002). The β3-subunit has a similar effect on Nav1.5, but it
increases persistent current through Nav1.2 in tsA-201 cells (cell
line derived from human embryonic kidney cells; Goldin, 2003).
β4-subunits disrupt VGSC inactivation in neurons, working as
endogenous open-channel blockers. This subunit has a short cyto-
plasmic tail that basically blocks the channel in the open state but
rapidly dissociates upon membrane repolarization to generate the
resurgent current in some neurons like Purkinje cells (Grieco et al.,
2005; Goldfarb, 2012).
Fast inactivation can be disrupted and transformed into long-
term inactivation by the interaction of theα-subunit of the channel
with a family of cytoplasmic proteins termed fibroblast growth
factor homologous factors (FHFs) (Goldfarb, 2012). FHFs act as
accessory channel subunits. Several FHFs delay fast inactivation
by raising the voltage at which fast inactivation occurs. Dover
et al. (2010) reported that all A-type FHFs (specially FHF2A
and FHF4A) exert a rapid onset of a distinct mode of long-term
inactivation of Nav1.6 and other VGSC including cardiac NaV1.5
(Dover et al., 2010; Goldfarb, 2012). A-type FHFs accomplish long-
term inactivation by providing an independent cytoplasmic gating
particle that competes with the channel’s intrinsic inactivating
particle for blockade of the channel upon membrane depolar-
ization. The authors reproduced this mechanism by injecting a
synthetic peptide corresponding to the A-type FHF particle that
mimics the long-term inactivation and opposes sustained firing
of excitable cells (Dover et al., 2010). β4-mediated channel block
and A-FHF-mediated long-term inactivation have a similar physi-
cal mechanism. Both processes are mediated by small cytoplasmic
particles that interact with the channel after the depolarization
has driven the channels into the open state. In both cases, the
blocking particles dock at similar sites deep within the cytoplas-
mic opening of the channel pore. The main difference between the
two processes is the rate of particle dissociation, where β4 particle
dissociates rapidly and FHF dissociates far more slowly (Goldfarb,
2012).
Slow inactivation is a different process that involves confor-
mational changes of the channel leading to rearrangement of the
pore. The process also involves segment 4 of domain IV and seg-
ments 5 and 6 of domain II (Goldin, 2003). This mechanism
is equivalent to the C-type inactivation mechanism described
for potassium channels (Rasmusson et al., 1998). Slow inactiva-
tion may play a role in regulating excitability by, for example,
modulating burst discharges. However, this modulation is com-
plicated since slow inactivation depends on both resting mem-
brane potential and the previous history of AP firing (Ulbricht,
2005).
In addition to fast and slow inactivation there is a third type
of inactivation named ultra-slow inactivation. This process was
described in Nav1.4 when the alanine in position 1529 (A1529) is
replaced by aspartate (D) in the domain IV P-loop (Goldin, 2003).
Binding of the fast inactivating particle inhibits this process. This
result demonstrates that there are interactions (mostly, allosteric
modulation) among the different inactivation events (Goldin,
2003).
“SODIUM CHANNEL PARTNERS” OR “CHANNEL
INTERACTIVE PROTEINS”
The current density and gating properties of VGSC can also be
modulated by the differential expression of channel “partners” or
ChiPs (Table 3). These terms designate molecules that affect the
aggregation, density, function, and regulation of VGSC. Up-to-
day, the main identified VGSC partners include caveolin-3 (and
the membrane compartment “caveolae”), CaMKII, connexin-43,
telethonin, plakophilin, ankyrins, fibroblast growth factor homol-
ogous factors (FHFs), nedd4, SAPs, and syntrophin/dystrophin
complex.
CAVEOLAE/CAVEOLIN-3
Caveolae are sarcolemmal membrane invaginations that have
been implicated in cellular trafficking cascades involving the β-
adrenergic receptors (β-AR; Schwencke et al., 1999; Rybin et al.,
2000). These membrane invaginations also contain scaffolding
proteins named “caveolins”. Yarbrough et al. (2002) demonstrated
both biochemically and functionally that caveolae are involved
in VGSC regulation by a mechanism involving the α-subunit of
the stimulatory G protein (Gαs) through the activation of the β-
ARs on the cell surface. Because direct Gαs activation induces an
increase in the number of functional channels at the sarcolemma
(Lu et al., 1999), they hypothesized that functional channels were
recruited from an intracellular store, allowing a faster presentation
of channels to the cell surface after β-stimulation. The authors
purified the caveolin-3 rich fraction using immunoprecipitation.
VGSC and Gαs are colocalized in the Cav3(+)-fraction, suggesting
a physical association of both proteins with the caveolar (Cav3-
rich) membrane (Rook et al., 2012). They also reported that the
increase in I Na induced by isoproterenol stimulation (10µM)
in the presence of a protein kinase A (PKA) inhibitor (PKA-
independent increase in I Na) was abolished when an anti-Cav3
antibody was injected into the cytoplasm of the cell through the
pipette. This suggests a direct action of the Gαs on the caveolae,
resulting in the presentation of caveolar VGSC to the sarcolemma.
Palygin et al. (2008) also demonstrated that the histidine residue
at position 41 of Gαs (H41) is a critical residue for the functional
increase of I Na observed.
CALMODULIN/CALMODULIN KINASE II
Tan et al. (2002) demonstrated that calmodulin regulates sodium
channel gating through binding to a region of 25 amino acids
located at the C-terminus of the intracellular domain. Wagner et
al. further studied the downstream signaling through Ca2+/CaM-
dependent protein kinase II (CaMKIIδ) in heart cells from two
heart failure animal models, where expression and activity of
CaMKII are increased by twofold to threefold. They demonstrated
that calmodulin regulates Na+ channel gating in part via CaMKII.
Using two cell models of CaMKII overexpression, they concluded
that both acute and chronic overexpression of CaMKIIδc signifi-
cantly shifted voltage-dependence of Na+ channel availability by
−6 mV, and the shift was Ca2+-dependent. CaMKII also enhanced
the inactivation of the channel and slowed its recovery from inac-
tivation. These effects were prevented using CaMKII inhibitors
(KN93 or AIP). CaMKII over-expression also increased persistent
(late) inward I Na and the intracellular Na+ concentration (also
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Table 3 | VGSC protein partners.
Gene Chromosome Protein Expression site and function Reference
Cav3 3p25.3 Caveolin-3 Scaffolding protein within caveolar membranes. Also
involved in VGSC regulation by a mechanism involving the
α subunit of the stimulatory G protein (Gαs) through the
activation of the βARs on the cell surface
Lu et al. (1999), Schwencke et al.
(1999), Rybin et al. (2000),Yarbrough
et al. (2002)
CALM 2 2p21 Calmodulin “Calcium-Modulated Protein.” Ca2+-binding protein
expressed in all eukaryotic cells
Tan et al. (2002)
CAMK 2A 5q32 CaMKII Part of a family of serine/threonine kinases that mediate
many of the second messenger effects of Ca2+
Wagner et al. (2006)
GJA1 6q22.31 Connexin-43 Connexins are assembled in groups of six to form
hemichannels, or connexons, and two hemichannels then
combine to form a gap junction.The connexin gene family
is diverse, with 21 identified members in the sequenced
human genome
Sato et al. (2011)
TCAP 17q12 Telethonin Small protein mainly expressed in skeletal muscle that
binds to and is phosphorylated by titin kinase and pro-
tein kinase D. Both proteins serve as a scaffold to which
myofibrils and other muscle related proteins are attached
Valle et al. (1997), Mayans et al.
(1998), Mues et al. (1998), Furukawa
et al. (2001), Knoll et al. (2002),
Haworth et al. (2004), Kojic et al.
(2004), Mazzone et al. (2008)
PKP2 12p11 Plakophilin-2 Fundamental component of the cardiac desmosome,
structure present in the intercalated disc
Sato et al. (2009)
ANK2 4q25–27 Ankyrin-B (or
ankyrin-2)
Cell membrane proteins that link the integral proteins of
the membrane to the underlying spectrin-actin cytoskele-
ton. Mutations in these genes have been related to long
QT syndrome type 4 (ANK2) and Brugada like-syndrome
(ANK3)
Jenkins and Bennett (2001),Garrido
et al. (2003), Lemaillet et al. (2003),
Mohler et al. (2004)
ANK3 10q21 Ankyrin-G (or
ankyrin-3)
FGF3 11q13/13.3 FHFs (FGFs) Family of cytoplasmic proteins termed fibroblast growth
factor homologous factors that can delay fast inactivation
of VGSC
Dover et al. (2010)
FGF5 4q21/21–21
FGF6 12q13/13.32
FGF11 17p13.1
FGF12 3q28/29
FGF13 Xq26.3/27.1
FGF14 13q33.1/34
Nedd4 Human 15q–15q21.3 Nedd4 Ubiquitin-protein ligases Rougier et al. (2005)
SNTG 1 8q11.21 Syntrophin The protein encoded by this gene is a member of the
syntrophin family. Syntrophins are cytoplasmic periph-
eral membrane proteins that typically contain 2 pleckstrin
homology (PH) domains, a PDZ domain that bisects the
first PH domain, and a C-terminal domain that mediates
dystrophin binding. This gene is specifically expressed in
the brain
Gavillet et al. (2006), Haenggi and
Fritschy (2006), Shao et al. (2009)
DMD Xp21.2 Dystrophin Rod-shaped cytoplasmic protein, and a vital part of a pro-
tein complex (costamere or dystrophin-assoc. prot.s) that
connects the cytoskeleton of a muscle fiber to the sur-
rounding extracellular matrix through the cell membrane
SCN1B-SCN4B 19q13.1 (SCN1B) and
11q23 (SCN2B–4B)
β subunits of
VGSC
Regulatory subunits ofVGSC expressed in CNS, PNS, and
heart (see alsoTables 1 and 2)
Isom et al. (1994), Kazarinova-Noyes
et al. (2001), Chen et al. (2004),
McEwen and Isom (2004), Meadows
and Isom (2005)
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prevented using CaMKII inhibitors). They reported that CaMKII
coimmunoprecipitates with and phosphorylates sodium channels.
In vivo data suggested that CaMKII overexpression mice were more
prone to suffer ventricular arrhythmias, particularly monomor-
phic ventricular tachycardia. The data as a whole supports the
hypothesis that CaMKII regulates sodium channel function in
myocytes most likely by association with and phosphorylation of
the channels (Wagner et al., 2006).
TELETHONIN
Telethonin is a small protein (19 kDa) that is mainly expressed
in striated muscle (Valle et al., 1997). This protein binds to and
is phosphorylated by titin kinase (Mayans et al., 1998) and pro-
tein kinase D (Haworth et al., 2004). One of its many functions
includes acting as a stretch sensor in the heart (Knoll et al., 2002),
linking sarcomeres to K+ channel subunits (Furukawa et al., 2001),
and interacting with titin (Mues et al., 1998) and ankyrin-2 (also
proposed to behave as stress sensors in muscle; Kojic et al., 2004).
Mazzone et al. (2008) hypothesized that telethonin may be rel-
evant in tissues different from striated muscle, where it might
also behave as a ChiP. After screening 20 unrelated patients with
primary intestinal pseudo-obstruction, the authors identified a
patient with a heterozygous mutation, R76C, in the telethonin
gene by direct DNA sequencing. The mutation is located in the
region of telethonin where the protein has been shown to inter-
act with sarcomeric proteins (muscle LIM protein and titin) in
the heart. Using immunostaining and immunoprecipitation they
demonstrated that telethonin and NaV1.5 were colocalized in
mouse hearts. They studied the effects of the R67C mutation on
the in vitro electrophysiology of SCN5A expressed in a Human
embryonic kidney cell line (HEK)-293. The coexpression of R67C
telethonin with SCN5A resulted in a leftward shift in the steady-
state activation of the sodium channel, leading to increased Na+
entry at resting potential (depolarizing effect). The data supports
the hypothesis that telethonin acts as a ChiP (Mazzone et al., 2008).
PLAKOPHILIN
Plakophilin-2 (PKP2) is a fundamental component of cardiac
desmosomes. This structure is present in the intercalated disk, the
site of end-to-end contact between cardiac myocytes, and provides
mechanical integrity between adjacent cells. NaV1.5 is also highly
localized at the intercalated disks. Combining immunochemistry
and electrophysiological studies Sato et al. (2009) demonstrated
that PKP2 associates with NaV1.5 in the same molecular complex,
and that the knockout of PKP2 expression produced a decrease
in peak current density, a shift in voltage-dependence inactiva-
tion, and a prolongation of time-dependence of recovery from
inactivation.
CONNEXIN-43
Connexin-43 peptides are localized at intercalated disks, where
they form gap junctions for electrical coupling of adjacent cells.
Sato et al. (2011) showed that AnkG, plakophilin, and connexin-43
are associated at the intercalated disks and that this macromolecu-
lar complex may interact with clusters of NaV1.5 also present in the
disk. More recently, Chourko et al. characterized the remodeling
of the gap junction (connexin-43) and VGSC in an ovine model
of right ventricular pressure overload induced by pulmonary
hypertension. The authors reported significant lateralization of
connexin-43,which was colocalized with mechanical junction pro-
teins and microtubule-associated proteins EB1 and Kifb5 (these
proteins are responsible for the forward trafficking of connexin-
43 to the intercalated disk). There was also a significant reduction
in the peak I Na and in V1/2 activation, a slower recovery from inac-
tivation, with no lateralization of the VGSC (NaV1.5). The authors
then speculate that the difference in the NaV1.5 remodeling respect
to the connexin-43 could be explained due to the fact that traf-
ficking of NaV1.5 might require molecules that cannot redirect the
channel to the lateral membrane. In summary, the data reported
support the idea of a partnership between these complexes, pre-
viously considered to be independent from each other (Chkourko
et al., 2012).
ANKYRINS
Ankyrins are a widely expressed family of “adaptor” proteins
responsible for the localization of proteins at specialized mem-
brane domains. From all the members that are included in the
ankyrin family, ankyrin-G (“G” from “general”) was initially stud-
ied in the brain. In neurons, ankyrin-G colocalizes and copurifies
with VGSC (Kordeli et al., 1995; Davis et al., 1996; Garrido et al.,
2003; Mohler, 2006). Ankyrin-G is important for the clustering of
NaV1.2 and 1.6 isoforms at the nodes of Ranvier (Jenkins and Ben-
nett, 2001; Garrido et al., 2003) and also colocalizes with VGSC at
the neuromuscular junction (Flucher and Daniels, 1989; Kordeli
et al., 1998). A role for ankyrin-G for VGSC targeting in cardiac
muscle was hypothesized based on the role of this protein in clus-
tering neuronal VGSC (Mohler, 2006). Ankyrin-G binds to a nine
residue domain in the DII–DIII loop in the α-subunit of VGSC
(Lemaillet et al., 2003). This binding is required for Nav1.5 local-
ization in heart cells (Garrido et al., 2003; Mohler et al., 2004).
Since ankyrin-G is primarily expressed at the intercalated disk
membrane and T-tubules, it colocalizes with Nav1.5 at these spe-
cific sites (Lemaillet et al., 2003; Mohler et al., 2004; Bennett and
Healy, 2008; Lowe et al., 2008). Mutations in either the sodium
channel domain at which ankyrin binds, or in ankyrin itself, can
affect the channel expression (Mohler et al., 2004).
FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTORS
Fibroblast growth factor homologous factors (FHFs) is a family of
cytoplasmic proteins that can interact with VGSC and delay fast
inactivation by raising the voltage at which fast inactivation occurs.
The role of FHFs as VGSC modulators was already discussed under
“Biophysical properties of VGSC.”
NEURONAL PRECURSOR CELL-EXPRESSED DEVELOPMENTALLY DOWN
REGULATED 4
Neuronal precursor cell-expressed developmentally down reg-
ulated 4 (Nedd4) is the prototypical protein in a family of
E3 ubiquitin. They select specific proteins for conjugation to
ubiquitin, which acts as a marker for protein degradation but
also in the sorting of proteins at different steps in biosynthetic
and endocytic pathways. They are found in the nucleus and at
the plasma membrane. Need4-2 refers to a subgroup of ubiquitin-
protein ligases that binds the PY motif of Nav1.5 and reduces the
sodium current (I Na) in HEK293 cells by promoting its inter-
nalization (Rougier et al., 2005). For more details see the review
written by Ingham et al. (2004).
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SYNAPSE-ASSOCIATED PROTEINS
Synapse-associated proteins (also called MAGUK, membrane-
associated guanylate kinase) are a family of proteins that
include Dlg, SAP97/hDlg, SAP90/PSD-95, SAP102, and PSD-
93/chapsyn110. They are composed of multiple sites of protein–
protein interactions, like the PDZ domains. SAP are localized
either to the pre- or postsynaptic sides of excitatory or inhibitory
synapses and play a central role in the molecular organization of
synapses, like PSD-95, SAP102, and distribution of the NMDA
glutamate receptor at the postsynaptic level. One of the family
members, SAP97, is also present in epithelial cells and localized at
the lateral membrane between cells (Fujita and Kurachi, 2000). At
the cardiomyocytes SAP97 colocalized with Nav1.5 at the interca-
lated disks, determining the existence of a second pool of sodium
channels in addition to the channels targeted at lateral membranes
by the syntrophin-dystrophin complex (Petitprez et al., 2011).
SYNTROPHIN/DYSTROPHIN COMPLEX
Syntrophins (α,β, andγ) bind and localize signaling proteins to the
plasma membrane (Shao et al., 2009). Syntrophins can also inter-
act with multiple proteins via two pleckstrin homology domains, a
PDZ domain and a conserved syntrophin unique region. The PDZ
domain can bind to the last three residues of the C-termini intra-
cellular domain of NaV1.4 and 1.5 (Haenggi and Fritschy, 2006).
The latter can also complex syntrophin and dystrophin (Gavil-
let et al., 2006). Syntrophin stabilizes the VGSC in the plasma
membrane and reduce its internalization (Shao et al., 2009).
β-SUBUNITS
In addition to the modulation of VGSC function (Johnson and
Bennett, 2006), β-subunits play critical roles in the intracellular
trafficking of α-subunits, regulating the channel expression levels
at the plasma membrane and their role in cell adhesion (Isom et al.,
1994). In vitro data suggests that β-subunits constitute commu-
nication links between adjacent cells, extracellular space (via their
interaction with tenascin-C and R), cytoskeleton and intracellular
signaling mechanisms, and other ion channels. In particular, the
β1-subunit seems to be critical for the interaction of the VGSC
with other CAMs and cytoskeletal proteins (Kazarinova-Noyes
et al., 2001; Chen et al., 2004; McEwen and Isom, 2004). Due
to their roles in the interactions with cytoskeletal proteins, CAMs,
and other ion channels, Meadows and Isom (2005) proposed that
β-subunits should also be considered as molecular scaffolds of
the ion conducting pore (α-subunits), therefore critically affecting
channel function, subcellular localization and cell surface expres-
sion in a cell-specific and subcellular domain-specific manner (see
Table 2).
PHARMACOLOGY OF VGSC
Voltage-gated sodium channels are the site of action of many tox-
ins and drugs. At least six sites of action for neurotoxins (sites
1–6) and one receptor site for class I antiarrhythmic drugs, local
anesthetics and related antiepileptic drugs are known to exist on
the VGSC (Cestele and Catterall, 2000). All of them are located
on the α-subunit of the channel. Receptor site 1 binds TTX and
saxitoxin (Noda et al., 1989; Hille, 2001). This receptor site is
formed by amino acid residues in the pore loops and on the
extracellular side of them at the outer end of the pore. The sen-
sitivity of the VGSC to TTX segregates them into two groups
(Table 1):
1. TTX-sensitive channels (TTX-S; blocked with TTX in the
nanomolar concentration range). This group includes Nav1.1,
NaV1.2, Nav1.3, Nav1.4, Nav1.6, and Nav1.7 isoforms.
2. TTX-resistant channels (TTX-R; blocked with TTX in the
micromolar-millimolar concentration range). This group
includes Nav1.5, Nav1.8, and Nav1.9 isoforms.
Biophysical and pharmacological properties of TTX-S and TTX-R
Na+ channels are different. TTX-R Na+ channels can be blocked
by inorganic (Co2+, Mn2+, Ni2+, Cd2+, Zn2+, La3+) and organic
Ca2+ channel blockers. Typically, TTX-R Na+ channels show
smaller single-channel conductance, slower kinetics, and a more
positive current-voltage relation than TTX-sensitive ones. Li and
Zhu (2011) recently reported two chimeric peptides of droso-
toxin that can block the activity of both TTX-R and TTX-S
channels. The authors proposed that this approach of understand-
ing the molecular determinants of toxins affecting VGSC would
allow a more rational design of subtype-specific sodium channel
blockers.
The overlapping sites of action of antiarrhythmic drugs, local
anesthetics and related antiepileptic drugs are located in the inner
cavity of the pore of the channel, and they are formed by amino
acid residues located in S6 in domains I, III, and IV (Ragsdale
et al., 1994, 1996; Hockerman et al., 1997; Catterall, 2000; Yarov-
Yarovoy et al., 2001, 2002; Liu et al., 2003a). Drug affinity can
be reduced by mutations in critical residues in the pore. Funda-
mentally, these drugs bind to their corresponding site of action
to change the function of the channel (decrease the sodium cur-
rent density). They can also change the affinity with which the
channel binds the drug depending on the functional conforma-
tion or state in which the channel is found (rest, active, inactive;
Bruton et al., 2011). Most sodium channel-blocking agents block
the channel when it is open or inactivated, and have very little
or no effect at all while the channel is in the resting state. Thus,
with each AP, the drug binds to the VGSC and blocks them, and
then dissociates during repolarization, with the consequent loss of
blockage.
The dissociation rate is a key determinant of steady-state
block of sodium channels. AP frequency and duration, membrane
potential level, and the physicochemical properties of the drug will
determine the rate of recovery from blockage. When depolariza-
tion frequency increases, the rest interval decreases, and so does the
time available for drug dissociation as the drug remains attached
to the channel for a longer time and consequently the steady-state
channel block increases. The increase in depolarization frequency
also represents repetitive openings of the pore that increase the
access of drugs to the intracellular site of action (use-dependent
block; Hille, 1977, 2001). The rate of recovery from blockage also
slows as cells are depolarized, as occurs during ischemia. Increased
AP duration results in a relative increase in the time the channel
remains in the inactive state and this can also increase the block
by drugs that mainly bind to sodium channels in the inactivated
state such as lidocaine.
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies July 2012 | Volume 3 | Article 124 | 10
Savio-Galimberti et al. Sodium channels, pharmacology, and channelopathies
Current treatment of neuropathic pain includes tricyclic anti-
depressants (amitriptyline, nortriptyline), local anesthetics (lido-
caine, mexiletine), and antiepileptic drugs (phenytoin, carba-
mazepine, lamotrigine). These drugs however have low efficacy
in terms of pain control and are associated with adverse effects
involving the heart and CNS.
DISEASES ASSOCIATED WITH VGSC MUTATIONS
(“CHANNELOPATHIES”)
Ten genes (SCN1A–SCN11A; Table 1) encoding the α-subunit
isoforms of the VGSC and four genes encoding the β-subunits
(SCN1B–SCN4B; Table 2) have been identified in the human
genome. Mutations in any of these genes can affect the structure
of the channel and, thus, its biophysical properties leading to the
development of “channelopathies” (Tables 1 and 2). All these con-
ditions are associated with autosomal dominant inheritance and de
novo mutations have been identified. These channelopathies can
be divided in four disease groups depending on the predominant
organ involved (George, 2005):
1. Brain sodium channelopathies, which include mutations in
SCN1A, SCN2A, SCN3A, and some mutations in SCN8A
observed in cases of familial human ataxia and in mice mod-
els of ataxia and end-plate diseases (these genes encode the
channels NaV1.1, NaV1.2,β1-subunit, and NaV1.6 respectively).
SCN1A, SCN2A, and SCN3A gene mutations may give rise to
epilepsy and epileptic/convulsive disorders.
2. Skeletal muscle sodium channelopathies. This group involves
mutations in the SCN4A, the gene that encodes the NaV1.4
isoform (skeletal muscle specific isoform). SCN4A gene muta-
tions are associated with myotonia, myasthenia syndromes, and
paralysis.
3. Cardiac sodium channelopathies, which involve mutations in
SCN5A (the gene that encodes NaV1.5, which is predominantly
found in cardiac muscle) and SCN10A (the gene that encodes
NaV1.8, which has been recently identified in the heart (Facer
et al., 2011; Verkerk et al., 2012; Yang et al., 2012) and has
been associated in genome-wide association studies (GWAS)
with alterations in the ventricular conduction (Chambers et al.,
2010; Sotoodehnia et al., 2010).
4. Peripheral nerve sodium channelopathies, which include muta-
tions in SCN9A (NaV1.7), SCN10A (NaV1.8), and SCN11A
(NaV1.9). Mutations in these genes have been associated with
peripheral pain syndromes (hyperalgesic syndrome) including
neuropathic and inflammatory pain.
BRAIN SODIUM CHANNELOPATHIES
The most commonly affected gene is SCN1A1,2. Functional stud-
ies of SCN1A missense epileptogenic mutations in vitro have been
controversial but several results are consistent with loss of function
(hypoexcitability) mutations (Ragsdale, 2008; Mantegazza et al.,
2010) and data obtained with animal models have confirmed this
(Tang et al., 2009; Martin et al., 2010). Data obtained with a mouse
model of Dravet syndrome expressing a truncated Nav1.1 showed
1www.molgen.ua.ac.be/SCN1AMutations
2http://www.scn1a.info/
that loss of function of this VGSC causes reduced sodium current
and excitability in GABAergic neurons, consistent with reduced
GABAergic inhibition (Yu et al., 2006). Nav1.1 missense muta-
tions can induce loss of function because of folding defects and
these mutants can be rescued by molecular interactions with co-
expressed proteins and drugs; this may be one of the causes of
the phenotypic variability in GEFS+ and may be exploited for
therapeutic potential (Escayg et al., 2000; Meisler and Kearney,
2005; Rusconi et al., 2007, 2009; Catterall et al., 2008). Epilepsy
has also been related with SCN1A mutations that alter channel
inactivation, resulting in persistent inward sodium current [gain-
of-function (hyperexcitability) mutations; Lossin et al., 2002]. The
above paragraph describes functional studies with Nav1.1 mutants
that yield a wide range of biophysical phenotypes from loss of
function to gain-of-function. At first sight this seems to be con-
tradictory. Therefore, questions arise as to how mutations with
such diverse functional effects can be associated with the same
epileptic syndrome or disease. To better understand this, it is crit-
ical to remember that SCN1A is widely expressed in most neurons
in the brain. It has also been previously reported that a single
sodium channel mutation can produce hyper- or hypoexcitabil-
ity in different types of neurons (Rush et al., 2006). Therefore,
the net effect of the SCN1A mutations on the brain excitability
will not only depend on the type of neuron where the mutant
channel is expressed but also on the electrical balance between
all the ionic currents that contribute to the neuronal AP and the
mutant currents. There also might be several additional patho-
genic mechanisms involved in the production of epilepsy that
are not completely understood yet but still make a significant
contribution to the production of the disease.
SMEI is a rare disorder characterized by generalized tonic,
clonic, or tonic-clonic seizures that are initially induced by fever
and begin during the first year of life. Typically, children with
Dravet syndrome [or myoclonic epilepsy of infancy (SMEI); Claes
et al., 2001] carry de novo mutations not inherited from their
parents. Later, patients also manifest other seizure types, includ-
ing absence, myoclonic, and simple and complex partial seizures.
Psychomotor development delay is observed around the second
year of life. SMEI is considered to be the most severe phenotype
within the spectrum of generalized epilepsies with febrile seizures-
plus. Because of this, genetic screening for SCN1A has become the
diagnostic tool for children with early-onset seizures. More than
half of the SMEI mutations cause loss of function as a result of
stop codons or deletions, leading to decreased levels of functional
sodium channels.
SCN1A mutations have also been associated with three other
epileptic disorders: intractable childhood epilepsy with gener-
alized tonic-clonic (ICEGTC) seizures, familial febrile convul-
sions type 3A (FEB3A), and familial hemiplegic migraine type
3 (FHM3). ICEGTC has been included in the Dravet syndrome
(Mullen and Scheffer, 2009). A mutation causing simple familial
febrile convulsions has been studied by Mantegazza et al. (2005).
Familial hemiplegic migraine type 3 is a distinct disease caused
by missense mutations of Nav1. Here again the functional effects
are controversial, but gain-of-function effects have been observed
and this is consistent with the pathogenic mechanism of migraines
with aura (Cestele et al., 2008; Kahlig et al., 2008).
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Missense mutations of SCN2A were also identified in a small
percentage of GEFS+ patients and mainly in patients with benign
familial neonatal-infantile seizures (BFNIS), a syndrome of mild
seizures that remit during the first year of life without neuro-
logic sequelae. BFNIS mutations produced abnormalities in the
sodium channels that led to a reduced channel activity (loss of
function; Misra et al., 2008). Other groups have reported muta-
tions in SCN2A that result in a gain-of-function, consistently with
the role of Nav1.2 in excitatory cortical neurons (Scalmani et al.,
2006; Liao et al., 2010).
The first SCN3A mutation (K353Q) was identified in a patient
with partial epilepsy resistant to antiepileptic drugs (Holland et al.,
2008). Even though the missense mutation described caused an
increase in late current, the pathogenic role of mutated Nav1.3 is
still debated. In mouse models, mutations in SCN8A lead to ataxia
and end-plate disease. These conditions can be reproduced by
conditional knockout of SCN8A in cerebellar Purkinje and gran-
ule cell neurons (Levin et al., 2006). In rare cases of human familial
ataxia, one frame-shift mutation has been identified in SCN8A that
truncates the protein at the DIV and lead to loss of channel func-
tion (Vicart et al., 2005; Trudeau et al., 2006) (For more detailed
information about mutations of brain VGSC see Catterall, 2010;
Mantegazza et al., 2010).
SKELETAL MUSCLE SODIUM CHANNELOPATHIES
The second group of channelopathies includes mutations in the
SCN4A gene, which is expressed in skeletal muscle. These skele-
tal muscle channelopathies (sodium channel myotonic disorders)
are part of a group of diseases called non-dystrophic myoto-
nias (Matheus et al., 2010). The clinical disorders can be split
between two groups based on the presence or absence of episodic
weakness: paramyotonia congenita (characterized by a marked
worsening of myotonia by cold and by the presence of clear
episodes of weakness), and sodium channel myotonia (notable
for the absence of episodic weakness but still have cold sensitiv-
ity). The latter group includes all the pure myotonic phenotypes,
including the potassium-aggravated myotonias (Fournier et al.,
2004).
Causative mutations in the SCN4A gene result in a gain
of sodium channel function that may show marked tempera-
ture dependence. Almost all mutations (over 40) that have been
described are missense mutations with an exception of a three base
pair deletion (Michel et al., 2007). Exons 22 and 24 are the main
exons involved in paramyotonia congenita, including mutations
T1313M, V1589M, and mutations at the R1448 and G1306 posi-
tion (Vicart et al., 2005; Matheus et al., 2008). Lerche et al. (1993)
reported a group of heterozygous mutations at the G1306 posi-
tion of the SCN4A gene. Electrophysiological studies on patient
muscle samples showed slower sodium fast channel inactivation
and an increase in late channel opening resulting in a steady-
state inward current, sustained muscle depolarization, and muscle
fiber hyperexcitability. These findings suggest that SCN4A residue
1306 is important for sodium channel inactivation (Lerche et al.,
1993).
Finally, numerous mutations in SCN4A gene have also been
related to hypokalemic periodic paralysis. This is a muscle dis-
ease characterized by episodes of extreme muscle weakness, and
it usually begins in infancy or early childhood. Most often,
these episodes involve a temporary inability to move muscles
in the arms and legs. Sokolov et al. (2007) reported three
mutations in gating-charge-carrying arginine residues in an S4
segment that cause hypokalemic periodic paralysis. The muta-
tions induce a hyperpolarization-activated cationic leak through
the voltage sensor of the skeletal muscle NaV1.4 channel, con-
sistent with a gain-of-function. This “gating pore current” is
active at the resting membrane potential and closed by depo-
larizations that activate the voltage sensor. The results reported
by these authors showed a clear correlation between muta-
tions that cause gating pore current and hypokalemic periodic
paralysis.
CARDIAC SODIUM CHANNELOPATHIES
Nav1.5, encoded by SCN5A, conducts the inward sodium cur-
rent (I Na) that initiates the cardiac AP. SCN5A-mediated late
sodium current also influences repolarization and refractoriness.
Mutations in the SCN5A gene result in alterations in the func-
tion of the α-subunit of the cardiac isoform Nav1.5 channel that
have been associated with several inherited arrhythmia syndromes.
The main entities related to SCN5A mutations include an auto-
somal dominant form of the LQTS (LQT3; Wang et al., 1995),
BS (Probst et al., 2003), progressive cardiac conduction disease
(CCD; Scott et al., 1999), sinus node dysfunction (SND; Benson
et al., 2003), AF (Olson et al., 2005; Darbar et al., 2008), atrial
standstill (Tan, 2006; Remme et al., 2008), and dilated cardiomy-
opathy (DCM; McNair et al., 2004). Most of these diseases are
associated with an increased risk of sudden cardiac death (SCD).
The malfunction of the β-subunits (β1 through β4) as well as
some of the protein partners that interact with Nav1.5 α-subunit
(like caveolin-3 and α-1 syntrophin) have been recently associated
with diseases that resemble these arrhythmia phenotypes (Vatta
et al., 2006; Cronk et al., 2007; Wu et al., 2008; Watanabe et al.,
2009).
Long QT syndrome is characterized by a cardiac repolarization
abnormality, with a prolonged QT interval duration observed on
12-lead ECG and vulnerability to a polymorphic ventricular tachy-
cardia called Torsade de Pointes. About 5–10% of LQTS cases are
related to mutations in SCN5A (LQT3) or the genes that encode
the ChiPs. Mutations in SCN5A compromise the II–IV linker and
disrupt fast inactivation, allowing repeated reopening of the chan-
nel during sustained depolarization. As a consequence, a small
persistent sodium current is evoked during the AP plateau. This
excessive inward current (gain-of-function) delays the repolariza-
tion of the cell, prolonging AP duration, and increasing the risk
for ventricular arrhythmias.
Brugada Syndrome is a genetic disease that has been associated
with ventricular fibrillation and SCD in young people. Approxi-
mately 20% of these patients have mutations in the SCN5A gene.
More than 200 mutations have been associated with this disease
(Kapplinger et al., 2010). In contrast to LQTS3 mutations, SCN5A
mutations related to BS result in a loss of function of the channel.
This can be produced by a confluence of different mechanisms,
such as trafficking defects, generation of defective or truncated
proteins, faster channel inactivation, shift of voltage-dependence
inactivation toward a more depolarized membrane potential, or
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even slow recovery from inactivation. The electrical consequence
of this is the presence of a slower conduction substrate. BS has
also been associated with mutations in the genes that encode β1-
(SCN1B, BS type 5) and β3-subunits (SCN3B, BS type 7; Abriel,
2010) of the cardiac sodium channel.
Genetic mutations in SCN5A specific only to AF have recently
been described. Recently, Li et al. (2009) identified a novel cod-
ing variant, K1493R, which altered a highly conserved residue in
the DIII–IV linker and was located six amino acids downstream
from the fast inactivation motif of sodium channels. Biophys-
ical studies of K1493R in tsA-201 cells demonstrated a signifi-
cant positive shift in voltage-dependence of inactivation and a
large ramp current near resting membrane potential, indicating
a gain-of-function. Enhanced cellular excitability was observed in
transfected HL-1 atrial cardiomyocytes, including spontaneous AP
depolarizations and a lower threshold for AP firing. These novel
biophysical observations provide molecular evidence linking cel-
lular “hyperexcitability” as a mechanism inducing vulnerability to
AF.
Other pathologies related to mutations in SCN5A include
progressive familial heart block type 1A (PFHB1A), sick sinus
syndrome type 1 (SSS1), sudden infant death syndrome (SIDS),
familial atrial standstill, and DCM. For a more detailed review
on SCN5A channelopathies see Zimmer and Surber (2008), and
Wilde and Brugada (2011).
In addition to SCN5A mutations, variants in SCN10A (the gene
that encodes NaV1.8) can also lead to alterations in the cardiac
rhythm. NaV1.8 has only recently been identified in the heart
(Facer et al., 2011; Verkerk et al., 2012) and GWAS have identified
common genetic variants in this gene that modulate ventricular
conduction (Chambers et al., 2010; Sotoodehnia et al., 2010).
PERIPHERAL NERVE SODIUM CHANNELOPATHIES
Lampert et al. and Theile and Cummins, recently published exten-
sive reviews on the role of sodium channels in chronic and neuro-
pathic pain syndromes (Lampert et al., 2010; Theile and Cummins,
2011). Neuropathic pain is defined as “pain caused by a lesion or
disease of the somatosensory nervous system,” and can be divided
into central and peripheral neuropathic pain. Typical examples
of neuropathic pain include post-herpetic neuralgia, painful dia-
betic neuropathy, phantom limb pain, and spinal cord injury
pain. The fundamental mechanism involved in the production
of neuropathic pain is an increase in nerve excitability (and thus
changes in VGSC properties), generally manifested in impulses
generated ectopically or with minimal stimulation. Nerve injury
(classically associated with neuropathic pain) can result in changes
in sodium channel trafficking, gene expression, and/or channel
kinetics, all of which contribute to neuronal membrane remodel-
ing and hyperexcitability associated with neuropathic pain (Devor,
2006). VGSC Nav1.7, Nav1.8, and Nav1.9 have been particularly
identified in the PNS (peripheral neurons and DRG neurons)
and seem to have a central role in the genesis of neuropathic
pain. Thus, these channels are the new targets for analgesia in
peripheral neuropathy pain syndromes. In particular, Nav1.7 is
considered to be one of the main mediators of peripheral pain.
It has been recently reported that Nav1.8 sodium channel is part
of the molecular machinery involved in mechanotransduction of
joint pain and other pain syndromes (Schuelert and McDougall,
2012). On the other hand, the role of Nav1.3 in diseased states is
still controversial.
Recent human association studies have directly linked SCN9A,
the gene that encodes Nav1.7, to three human pain disorders:
dominantly inherited gain-of-function mutations in inherited ery-
thromelalgia (IEM; nine mutations), paroxysmal extreme pain
disorder (PEPD; eight mutations), and recessively inherited loss-
of-function mutations in Nav1.7-related congenital insensitivity
to pain (CIP; fourteen mutations) (Dib-hajj et al., 2009).
Inherited erythromelalgia (IEM) is a chronic neuropathic pain
syndrome that is characterized by excruciating painful attacks in
the extremities that begin in childhood and progress over life. A
shift to voltage-dependent activation toward more negative poten-
tials seems to be a common factor in all the mutations of SCN9A
that lead to this disease. This leftward shift of activation can lead
to a hyperexcitability state (gain-of-function mutations). Many
mutations also delay inactivation, and therefore, larger currents
result from slow depolarizing stimuli (“ramp currents”).
Paroxysmal extreme pain disorder (PEPD), previously referred
to as familial rectal pain (Fertleman et al., 2006), is character-
ized by severe pain accompanied by flushing which are induced
by bowel movements or probing of the perianal areas, and are
sometimes accompanied by tonic non-epileptic seizures, syncope,
bradycardia, and occasionally asystole.
Congenital insensitivity to pain (CIP) is characterized by com-
plete absence of pain perception in patients with non-functional
Nav1.7. These patients also exhibit partial anosmia. In this case, the
mutations in SCN9A identified introduce a stop codon leading to
the production of truncated proteins that are non-functional. For
further details on the mutations related to each of these diseases
see Lampert et al. (2010).
SUMMARY
Voltage-gated sodium channels are widely distributed in excitable
and non-excitable cells, and play a critical role in electrical acti-
vation in the body. VGSC constitute macromolecular complexes,
in which their function relies on both the specific structure of
the channel protein (α- and β-subunits) as well as their protein
partners (ChiPs). Since VGSC occur predominantly in the central
and PNS, and striated (skeletal and cardiac) muscles, mutations in
genes encoding VGSC and ChiPs will culminate in diseases named
“channelopathies” that can be grouped into four main categories:
epileptic syndromes, skeletal myopathies, cardiac arrhythmias, and
neuropathies (with pain-related syndromes). Pathologic condi-
tions can also arise from the up regulation of the VGSC, as for
example in highly aggressive prostate (Nav1.7) and breast (Nav1.5)
metastatic carcinomas, An improved understanding of the critical
role of the molecular composition of ion channel complexes, the
influence of protein partners, and the specific cellular domains
underlying protein interactions, are essential for the development
of new therapies to treat channelopathies associated with VGSC.
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